European Patent Office

T 1085/13 (Amorphous Lercanidipine Hydrochloride / Recordati) vom 09.11.2018

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2018:T108513.20181109
Datum der Entscheidung
9. November 2018
Aktenzeichen
T 1085/13
Antrag auf Überprüfung von
-
Anmeldenummer
06723128.2
Verfahrenssprache
Englisch
Verteilung
An die Kammervorsitzenden und -mitglieder verteilt (B)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
AMORPHOUS LERCANIDIPINE HYDROCHLORIDE
Name des Antragstellers
Recordati Ireland Limited
RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.
Name des Einsprechenden
-
Kammer
3.3.02
Leitsatz
-
Schlagwörter
Novelty - (yes)
Inventive step - (yes)
Orientierungssatz
A claim defining a compound as having a certain purity lacks novelty over a prior-art disclosure describing the same compound only if the prior art discloses the claimed purity at least implicitly, for example by way of a method for preparing said compound, the method inevitably resulting in the purity as claimed.
Such a claim, however, does not lack novelty if the disclosure of the prior art needs to be supplemented, for example by suitable (further) purification methods allowing the skilled person to arrive at the claimed purity.
The question of whether such (further) purification methods for the prior-art compound are within the common general knowledge of those skilled in the art and, if applied, would result in the claimed purity, is not relevant to novelty, but is rather a matter to be considered in the assessment of inventive step (reasons, 3.7, 3.8).

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the examining division with the order to grant a patent with the following claims and a description to be adapted thereto:

Claims 1 to 3 of the main request filed during the oral proceedings of 9 November 2018.